Stay updated with breaking news from 87162t20. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) CMO Rebecca Taub sold 27,845 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $245.14, for a total value of $6,825,923.30. Following the transaction, the chief marketing officer now directly owns 458,999 shares of the company’s […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Paul A. Friedman sold 18,710 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $242.96, for a total value of $4,545,781.60. Following the completion of the sale, the director now directly owns 185,735 […]
Profund Advisors LLC raised its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 32.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 7,723 shares of the biopharmaceutical company’s stock after buying an additional 1,898 shares during the quarter. Profund Advisors LLC’s holdings in Madrigal Pharmaceuticals were worth $1,128,000 at […]
Connor Clark & Lunn Investment Management Ltd. lowered its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 21.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 51,686 shares of the biopharmaceutical company’s stock after selling 14,075 shares during the […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective […]